Benefits of cladribine tablets on magnetic resonance imaging (MRI) outcomes in patients with multiple sclerosis: analysis of pooled double-blind data from the CLARITY and ONWARD studies

被引：0
|
作者：
Giovannoni, G. [1 ]
Comi, G. [2 ]
Montalban, X. [3 ]
Hicking, C. [4 ]
Dangond, F. [5 ]
机构：
[1] Queen Mary Univ London, Blizard Inst, Barts & London Sch Med & Dent, London, England
[2] Univ Vita Salute San Raffaele, Osped San Raffaele, Dept Neurol, Milan, Italy
[3] Hosp Univ Vall dHebron, Dept Neurol Neuroimmunol, Barcelona, Spain
[4] Merck KGaA, Darmstadt, Germany
[5] EMD Serono Inc, Billerica, MA USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2016年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P642
引用
收藏
页码：304 / 304
页数：1
相关论文
共 50 条
  • [21] Analysis of clinical and radiological disease activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets, in the double-blind, 96-week CLARITY study
    Giovannoni, G.
    Comi, G.
    Cook, S.
    Rammohan, K.
    Rieckmann, P.
    Soelberg-Sorensen, P.
    Vermersch, P.
    Chang, P.
    Hamlett, A.
    Fevr, T.
    Musch, B.
    Greenberg, S. J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2010, 17 : 215 - 215
  • [22] MRI outcomes of short-course oral treatment with cladribine tablets for relapsing-remitting multiple sclerosis (RRMS) in the 96-week, phase III, double-blind, placebo-controlled CLARITY study
    Comi, G.
    Cook, S.
    Giovannoni, G.
    Rammohan, K.
    Rieckmann, P.
    Soelberg-Sorensen, P.
    Vermersch, P.
    Chang, P.
    Hamlett, A.
    Musch, B.
    Fevr, T.
    Viglietta, V.
    Greenberg, S.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2009, 285 : S114 - S114
  • [23] Analysis of Clinical and Radiological Disease Activity-Free Status in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS) Treated with Cladribine Tablets, in the Double-Blind, 96-Week CLARITY Study
    Giovannoni, Gavin
    Cami, Giancarlo
    Cook, Stuart
    Rammohan, Kottil
    Rieckmann, Peter
    Sorensen, Per Soelberg
    Vermersch, Patrick
    Chang, Peter
    Hamlett, Anthony
    Veriee, Rehan
    Musch, Bruno
    Greenberg, Steven
    NEUROLOGY, 2010, 74 (09) : A295 - A296
  • [24] Effects of cladribine tablets on haematological profiles in patients with relapsing-remitting multiple sclerosis in the 96-week, phase III, double-blind, placebo-controlled CLARITY study
    Sorensen, P. S.
    Comi, G.
    Cook, S.
    Giovannoni, G.
    Rammohan, K.
    Rieckmann, P.
    Vermersch, P.
    Chang, P.
    Hamlett, A.
    Viglietta, V.
    Verjee, R.
    Musch, B.
    Greenberg, S.
    MULTIPLE SCLEROSIS, 2009, 15 (09): : S137 - S137
  • [25] Effects of cladribine tablets on peripheral lymphocyte subtypes implicated in multiple sclerosis immunopathogenesis: surface marker analysis for a subset of patients from the 96-week, phase III, double-blind, placebo-controlled CLARITY study
    Rieckmann, P.
    Comi, G.
    Cook, S.
    Giovannoni, G.
    Rammohan, K.
    Sorensen, P. S.
    Vermersch, P.
    Chang, P.
    Hamlett, A.
    Viglietta, V.
    Musch, B.
    Greenberg, S.
    MULTIPLE SCLEROSIS, 2009, 15 (09): : S248 - S249
  • [26] Haematological profiles in patients treated with cladribine tablets for relapsing-remitting multiple sclerosis (RRMS): results from the CLARITY study, a 96 week, phase III, double-blind, placebo-controlled trial
    Soelberg-Sorensen, P.
    Comi, G.
    Cook, S.
    Giovannoni, G.
    Rammohan, K.
    Rieckmann, P.
    Vermersch, P.
    Chang, P.
    Hamlett, A.
    Viglietta, V.
    Greenberg, S.
    JOURNAL OF NEUROLOGY, 2009, 256 : S127 - S128
  • [27] Safety and tolerability of cladribine tablets in relapsing-remitting multiple sclerosis during the 96-week, phase III, double-blind, placebo-controlled CLARITY study
    Cook, S.
    Vermersch, P.
    Comi, G.
    Giovannoni, G.
    Rammohan, K.
    Rieckmann, P.
    Sorensen, P. S.
    Chang, P.
    Hamlett, A.
    Musch, B.
    Viglietta, V.
    Greenberg, S.
    MULTIPLE SCLEROSIS, 2009, 15 (09): : S20 - S20
  • [28] Reduction in Healthcare and Societal Resource Utilization Associated with Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis Analysis of Economic Data from the CLARITY Study
    Ali, Shehzad
    Paracha, Noman
    Cook, Stuart
    Giovannoni, Gavin
    Comi, Giancarlo
    Rammohan, Kottil
    Rieckmann, Peter
    Sorensen, Per Soelberg
    Vermersch, Patrick
    Greenberg, Steven
    Scott, David A.
    Joyeux, Alexandre
    CLINICAL DRUG INVESTIGATION, 2012, 32 (01) : 15 - 27
  • [29] Cladribine tablets produce sustained improvements in relapsing-remitting multiple sclerosis in the 96-week, phase III, double-blind, placebo-controlled CLARITY study
    Rammohan, K.
    Vermersch, P.
    Comi, G.
    Cook, S.
    Giovannoni, G.
    Rieckmann, P.
    Sorensen, P. S.
    Chang, P.
    Hamlett, A.
    Musch, B.
    Verjee, R.
    Greenberg, S.
    MULTIPLE SCLEROSIS, 2009, 15 (09): : S249 - S249
  • [30] Tolerability Profile of Cladribine Tablets Therapy for Patients with Relapsing-Remitting Multiple Sclerosis: Factors Contributing to Treatment Completion in the Double-Blind, 96-Week, Placebo-Controlled CLARITY Study
    Vermersch, Patrick
    Comi, Giancarlo
    Cook, Stuart
    Giovannoni, Gavin
    Rammohan, Kottil
    Rieckmann, Peter
    Sorensen, Per Soelberg
    Kurukulasuriya, Nuwan C.
    Viglietta, Vissia
    Chang, Peter
    Papasouliotis, Orestis
    Greenberg, Steven J.
    NEUROLOGY, 2011, 76 (09) : A246 - A247
12345